Posted by Michael Wonder on 06 Feb 2026
Teva Canada announces approval of expanded indication of Ajovy (fremanezumab solution for subcutaneous injection), the first anti-CGRP preventive treatment for paediatric episodic migraine
4 February 2026 - Teva Canada announced today that Health Canada has approved an expanded indication for Ajovy (fremanezumab solution for subcutaneous injection) for the prevention of episodic migraine (fewer than 15 migraine days per month) in paediatric patients aged 6 to 17 years and weighing at least 45 kg.
With this approval, Ajovy becomes the first and only calcitonin gene-related peptide (CGRP) antagonist indicated for eligible paediatric patients, marking a meaningful advancement in expanding preventive treatment options for those living with migraine.
